New Drug Applications

Alkermes Receives Refusal to File Letter From FDA for ALKS 5461

8 years ago
by David Miller
962 Views
Written by David Miller

DUBLIN, April 2, 2018 /PRNewswire/ — Alkermes plc (Nasdaq: ALKS) today announced that it received a Refusal to File letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ALKS 5461, a once-daily, oral…Original Article

You may also like

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

View all posts
[mwai_chat window="true" fullscreen="true"]